Anxiety/QoL Scale from: ‐1 to 1 with 1 indicating best outcome · Adults with haematological malignancies
It is very uncertain whether physical exercise changes anxiety/QoL Scale from: ‐1 to 1 with 1 indicating best outcome compared with no physical exercise (very low certainty).
1 finding from 1 review
Fatigue · Adults with haematological malignancies
Physical exercise showed no clear difference in fatigue Scale from: ‐1 to 1 with 1 indicating best outcome compared with no physical exercise (moderate certainty).
1 finding from 1 review
Serious adverse events · Adults with haematological malignancies
It is very uncertain whether physical exercise changes serious adverse events compared with no physical exercise (very low certainty).
1 finding from 1 review
Death during study period · patients with a haematological condition who receive a haematopoietic stem cell transplant as treatment for their condition.
MSCs showed no clear difference in all‐cause mortality (prophylactic trials) (over duration of trial) compared with control/placebo (low certainty).
2 findings from 1 review
Safety of MSC infusion · patients with a haematological condition who receive a haematopoietic stem cell transplant as treatment for their condition.
1 finding from 1 review
Health‐related quality of life · patients with a haematological condition who receive a haematopoietic stem cell transplant as treatment for their condition.
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Relapse of malignant disease (prophylactic trials) (>12‐month · patients with a haematological condition who receive a haematopoietic stem cell transplant as treatment for their condition.
MSCs showed no clear difference in relapse of malignant disease (prophylactic trials) (>12‐month compared with control/placebo (low certainty).
1 finding from 1 review
Incidence of acute GvHD (prophylactic trials) · patients with a haematological condition who receive a haematopoietic stem cell transplant as treatment for their condition.
MSCs showed no clear difference in incidence of acute GvHD (prophylactic trials) compared with control/placebo (low certainty).
1 finding from 1 review
Incidence of chronic GvHD (prophylactic trials) · patients with a haematological condition who receive a haematopoietic stem cell transplant as treatment for their condition.
MSCs may leads to lower incidence of chronic GvHD (prophylactic trials) compared with control/placebo (low certainty).
1 finding from 1 review
Acute GvHD complete response (therapeutic trials) · patients with a haematological condition who receive a haematopoietic stem cell transplant as treatment for their condition.
It is very uncertain whether MSCs changes acute GvHD complete response (therapeutic trials) compared with control/placebo (very low certainty).
1 finding from 1 review
Chronic GvHD complete response (therapeutic trials) · patients with a haematological condition who receive a haematopoietic stem cell transplant as treatment for their condition.
It is very uncertain whether MSCs changes chronic GvHD complete response (therapeutic trials) compared with control/placebo (very low certainty).
1 finding from 1 review
All‐cause mortality up to 30 days № of participants: 72 (1 RCT) · patients undergoing non‐cardiac surgery/invasive procedures
It is very uncertain whether prophylactic plasma transfusion before surgery/invasive procedures changes all‐cause mortality up to 30 days № of participants: 72 (1 RCT) compared with no prophylactic plasma transfusion before surgery/invasive… (very low certainty).
1 finding from 1 review
RR 0.38 [0.13, 1.1]
Studies not reported
Very low
Number of transfusions per participant within 7 days ‐ not reported · patients undergoing non‐cardiac surgery/invasive procedures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Blood transfusion · patients undergoing non‐cardiac surgery/invasive procedures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events measured by plasma transfusion‐related complications within 24 hours № of participants: 21 (1 RCT) · patients undergoing non‐cardiac surgery/invasive procedures
It is very uncertain whether prophylactic plasma transfusion before surgery/invasive procedures changes serious adverse events measured by plasma transfusion‐related… compared with alternative haemostatic agents (very low certainty).
1 finding from 1 review
RR 9.82 [0.59, 162.24]
Studies not reported
Very low
Serious adverse events measured by surgery or procedure‐related complications within 30 days ‐ not reported · patients undergoing non‐cardiac surgery/invasive procedures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life ‐ not reported · patients undergoing non‐cardiac surgery/invasive procedures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality up to 30 days ‐ not reported · patients undergoing non‐cardiac surgery/invasive procedures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Major bleeding · patients undergoing non‐cardiac surgery/invasive procedures
It is very uncertain whether thromboelastography threshold changes major bleeding within 24 hours № of participants: 60 (1 RCT) compared with standard of care (laboratory parameters) (very low certainty).
1 finding from 1 review
RR 0.33 [0.01, 7.87]
Studies not reported
Very low
Number of transfusions per participant within 7 days ‐ not reported · patients undergoing non‐cardiac surgery/invasive procedures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found